Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” oregon “the Company"), a biotech institution focused connected find and improvement of caller psychedelic-derived therapeutics to lick large under-treated wellness problems, contiguous announced that arsenic portion of its ongoing collaboration with the Bar-Ilan University, Israel and Professor Gal Yadid, from the Gonda Multidisciplinary Brain Research Center, a caller pre-clinical proceedings (the “trial") resulted successful affirmative outcomes successful narration to treating Major Depressive Disorder (“MDD”).
The proceedings evaluated 2-Fluorodeschloroketamine’s (“2-FDCK”), an innovative analogue of Ketamine, of which the Company has a pending patent with the United States Patent and Trademark Office, for its usage successful treating slump including attraction resistant depression.
The intent of this proceedings was to find 2-FDCK's effect connected the motivational authorities of rodents arsenic a attraction for depressive behaviour and to trial 2-FDCK arsenic a imaginable caller semipermanent pharmacological psychoactive attraction for MDD. In the trial, the Flinders Sensitive Line (“FSL”) rat, an carnal exemplary of depression, were treated either by Ketamine oregon 2-FDCK for 14 consecutive days.
The results indicated precocious imaginable safely treating some acute and chronic depression, compared to Ketamine that is utilized contiguous for treating depression. The results suggest that determination is simply a superior effect of 2-FDCK vs. Ketamine connected the depressive-like behaviour of the FSL carnal model: Both Ketamine and 2-FDCK affected depressive-like symptoms. However, the effect was longer lasting erstwhile utilizing a chronic attraction paradigm, lone for 2-FDCK.
“One of our goals of moving intimately with starring researchers astir the world, is to analyse our proprietary compounds for caller revolutionary treatments for addictions and intelligence wellness disorders. Our beardown IP portfolio, includes galore innovative compounds successful the tract of psychedelic-derived therapeutics," said Clearmind's CEO Dr. Adi Zuloff-Shani. "We are precise encouraged by these preclinical information arsenic we judge this could marque a tremendous quality to patients suffering with treatment-resistant depression, who person constricted options disposable to them.”
About Clearmind Medicine Inc.
Clearmind is simply a psychedelic pharmaceutical biotech institution focused connected the find and improvement of caller psychedelic-derived therapeutics to lick wide and underserved wellness problems, including intoxicant usage disorder. Its superior nonsubjective is to probe and make psychedelic-based compounds and effort to commercialize them arsenic regulated medicines, foods oregon supplements.
The company’s intelligence portfolio presently consists of 7 patent families. The institution intends to question further patents for its compounds whenever warranted and volition stay opportunistic regarding the acquisition of further intelligence spot to physique its portfolio.
Shares of Clearmind are listed for trading connected Nasdaq and the Canadian Securities Exchange nether the awesome "CMND" and the Frankfurt Stock Exchange nether the awesome “CWY”.
For further accusation visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
FORWARD-LOOKING STATEMENTS:
This property merchandise contains “forward-looking statements” wrong the meaning of the Private Securities Litigation Reform Act and different securities laws. Words specified arsenic “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and akin expressions oregon variations of specified words are intended to place forward-looking statements. For example, the Company is utilizing forward-looking statements erstwhile it discusses the results of preclinical trials, conducting aboriginal trials, the results of aboriginal projects, the submission of patent applications and that psychedelic based treatments clasp imaginable to code and supply dedicated solutions for assorted intelligence wellness conditions. Forward-looking statements are not humanities facts, and are based upon management’s existent expectations, beliefs and projections, galore of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed successful bully faith. However, determination tin beryllium nary assurance that management’s expectations, beliefs and projections volition beryllium achieved, and existent results whitethorn disagree materially from what is expressed successful oregon indicated by the forward-looking statements. Forward-looking statements are taxable to risks and uncertainties that could origin existent show oregon results to disagree materially from those expressed successful the forward-looking statements. For a much elaborate statement of the risks and uncertainties affecting the Company, notation is made to the Company’s reports filed from clip to clip with the Securities and Exchange Commission (“SEC”), including, but not constricted to, the risks elaborate successful the Company’s last prospectus (registration No. 333-265900) filed with the SEC connected November 16, 2022. Forward-looking statements talk lone arsenic of the day the statements are made. The Company assumes nary work to update forward-looking statements to bespeak existent results, consequent events oregon circumstances, changes successful assumptions oregon changes successful different factors affecting forward-looking accusation but to the grade required by applicable securities laws. If the Company does update 1 oregon much forward-looking statements, nary inference should beryllium drawn that the Company volition marque further updates with respect thereto oregon with respect to different forward-looking statements. References and links to websites person been provided arsenic a convenience, and the accusation contained connected specified websites is not incorporated by notation into this property release. Clearmind is not liable for the contents of third-party websites.
English (US)